INOVIO’s Q3 2025 showed a larger net loss primarily due to a $22.5M non-cash loss from fair value adjustments on warrant liabilities. Operating expenses declined year-over-year, driven by reductions in R&D and G&A costs. The company completed the BLA submission for INO-3107 and is preparing for a potential commercial launch in mid-2026.

Inovio reduced its net loss to $23.5M in Q2 2025 as R&D and G&A expenses declined. While revenue remained at zero, the company continued to focus on progressing INO-3107 towards regulatory submission and bolstered its cash position with a $22.5M capital raise in July.

Inovio reported a smaller net loss in Q1 2025 due to reduced R&D and G&A expenses. Revenue from collaborative arrangements reappeared after a zero-revenue quarter in Q1 2024. The company continues to prepare for BLA submission for INO-3107 and advances its DMAb technology.

Inovio generated $117,000 in revenue in Q4 2024, a slight increase from the previous year. The company reported a net loss of $19.4 million for the quarter and continued its progress toward BLA submission and future clinical trials, while maintaining sufficient cash reserves.

INOVIO's primary focus is driving toward the regulatory approval and commercialization of its lead product candidate, INO-3107. The company is preparing regulatory submissions for INO-3107 and expects to have all non-device BLA modules completed by the end of 2024, with BLA submission targeted for mid-2025.

INOVIO reported a net loss of $32.2 million for the second quarter of 2024, with cash, cash equivalents, and short-term investments totaling $110.4 million as of June 30, 2024. The company is facing manufacturing issues with its CELLECTRA® device, delaying the BLA submission for INO-3107 to mid-2025.

INOVIO reported a net loss of $30.5 million for the first quarter of 2024. The company is on track to submit its BLA for INO-3107 in the second half of 2024 and is advancing plans for a Phase 3 trial of INO-3112. INOVIO's cash runway is projected into the third quarter of 2025.

INOVIO reported third quarter results with significant progress on INO-3107, including Breakthrough Therapy designation and FDA feedback supporting a BLA submission under the accelerated approval program. The company is focused on commercialization strategy and aligning resources with late-stage clinical candidates.

Inovio announced its Q2 2023 financial results, highlighting progress with INO-3107 and a strategic update including pipeline reprioritization and corporate reorganization with a focus on late-stage clinical programs. The company is preparing to initiate a pivotal Phase 3 trial of INO-3107 in adult RRP patients in the first quarter of 2024. INOVIO is stopping investment in VGX-3100 for cervical HSIL for U.S. market. A headcount reduction and reallocation of resources are expected to lower future cash burn and extend cash runway into the third quarter of 2025.

Inovio reported a net loss of $40.6 million, or $0.16 per share, for the quarter ended March 31, 2023. The company ended the quarter with $223.8 million in cash, cash equivalents and short-term investments and expects its cash runway to extend into the first quarter of 2025.

INOVIO reported Q4 2022 financial results, with a total revenue of $125,000 and a net loss of $54.5 million, or $0.22 per share. The company ended the year with $253 million in cash, cash equivalents, and short-term investments, maintaining its cash runway projections into the first quarter of 2025.

INOVIO reported total revenue of $9.2 million for the three months ended September 30, 2022, compared to $292,000 for the same period in 2021. The net loss for the quarter ended September 30, 2022, was $37.8 million, or $0.15 per basic and diluted share, compared to net loss of $60.2 million, or $0.29 per basic and diluted share, for the quarter ended September 30, 2021.

INOVIO reported a revenue of $784,000 for the second quarter of 2022, an increase from $273,000 in the same period of 2021. The net loss for the quarter was $108.5 million, compared to a net loss of $82.1 million for the quarter ended June 30, 2021.

INOVIO reported total revenue of $199,000 for the three months ended March 31, 2022, compared to $371,000 for the same period in 2021. The net loss for the quarter was $79.1 million, or $0.36 per basic and diluted share, compared to a net loss of $54.4 million, or $0.27 per basic and diluted share, for the quarter ended March 31, 2021.

Inovio reported Q4 2020 financial results, with a total revenue of $5.6 million and a net loss of $24.3 million, or $0.14 per share. The company highlighted progress in its HPV and oncology programs, including positive results from the REVEAL 1 Phase 3 clinical trial for VGX-3100 and advancements in its COVID-19 vaccine program.